<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.107196</article-id><article-id pub-id-type="publisher-id">ACM-36492</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200700000_24345177.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  结核分枝杆菌耐药分子机制的研究进展
  Research Progress on Molecular Mechanism of Drug Resistance of Mycobacterium tuberculosis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>兰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>秋莲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>南宁市第二人民医院，广西 南宁</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>07</month><year>2020</year></pub-date><volume>10</volume><issue>07</issue><fpage>1292</fpage><lpage>1297</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目前许多地区结核病的发病率和病死率出现上升现象，但抗结核药物的泛滥及不合理应用，所致耐药结核分枝杆菌的出现，阻碍了结核病的诊断和治疗。因此了解结核分枝杆菌耐药分子机制和常见药物耐药分子机制，对制定有效的治疗方案，及时诊断、有效治疗结核病，改善结核患者预后具有重大意义。本文对结核分枝杆菌的耐药分子机制及常用抗结核药物的耐药分子机制进行总结，以为临床提供参考。
    At present, the incidence and mortality of tuberculosis are increasing in many areas, but the proliferation and unreasonable application of anti-tuberculosis drugs have led to the emergence of drug-resistant Mycobacterium tuberculosis, which has hindered the diagnosis and treatment of tuberculosis. Therefore, understanding the molecular mechanism of drug resistance and common drug resistance of Mycobacterium tuberculosis is of great significance for formulating effective treatment programs, timely diagnosis and effective treatment of tuberculosis, and improving the prognosis of tuberculosis patients. This article summarizes the drug-resistant molecular mechanism of Mycobacterium tuberculosis and the drug-resistant molecular mechanisms of commonly used anti-tuberculosis drugs, so as to provide clinical reference. 
  
 
</p></abstract><kwd-group><kwd>结核分枝杆菌，耐药分子机制, Mycobacterium tuberculosis</kwd><kwd> Molecular Mechanisms of Drug Resistance</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>结核分枝杆菌耐药分子机制的研究进展<sup> </sup></title><p>杨兰，吴秋莲</p><p>南宁市第二人民医院，广西 南宁</p><p>收稿日期：2020年6月14日；录用日期：2020年7月7日；发布日期：2020年7月14日</p><disp-formula id="hanspub.36492-formula13"><graphic xlink:href="//html.hanspub.org/file/22-1571409x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目前许多地区结核病的发病率和病死率出现上升现象，但抗结核药物的泛滥及不合理应用，所致耐药结核分枝杆菌的出现，阻碍了结核病的诊断和治疗。因此了解结核分枝杆菌耐药分子机制和常见药物耐药分子机制，对制定有效的治疗方案，及时诊断、有效治疗结核病，改善结核患者预后具有重大意义。本文对结核分枝杆菌的耐药分子机制及常用抗结核药物的耐药分子机制进行总结，以为临床提供参考。</p><p>关键词 :结核分枝杆菌，耐药分子机制</p><disp-formula id="hanspub.36492-formula14"><graphic xlink:href="//html.hanspub.org/file/22-1571409x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/22-1571409x7_hanspub.png" /> <img src="//html.hanspub.org/file/22-1571409x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>结核病(Tuberculosis, TB)是由结核分枝杆菌(Mycobacterium tuberculosis, MTB)引起的严重危害人类健康的慢性致死性传染病，因其病程长、治疗费用较高、药物不良反应大，现成为全球关注的公共卫生和社会问题，也是我国需重点控制的疾病之一 [<xref ref-type="bibr" rid="hanspub.36492-ref1">1</xref>]。由于抗结核药物的泛滥及不合理使用，目前结核病耐药情况愈发严重，出现了耐多药结核病(multidrug-resistant tuberculosis, MDR-TB)及广泛耐药结核病(extensively drug-resistant tuberculosis, XDR-TB) [<xref ref-type="bibr" rid="hanspub.36492-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.36492-ref3">3</xref>]。因此深入了解结核分枝杆菌及抗结核药物的耐药机制，对遏制耐药结核病蔓延具有重要意义。本文就结核分枝杆菌及主要药物的耐药分子机制综述如下。</p></sec><sec id="s4"><title>2. 结核分枝杆菌发生耐药的分子机制</title><p>基因突变是结核分枝杆菌发生耐药的分子机制。抗结核药物作用靶点及相关代谢酶的基因突变导致结核分枝杆菌对单一药物产生耐受性，多种药物靶基因突变的累加则是导致结核分枝杆菌耐多药产生的原因 [<xref ref-type="bibr" rid="hanspub.36492-ref4">4</xref>]，且不同药物耐药突变株出现的几率不同，突变导致的耐药程度也不同 [<xref ref-type="bibr" rid="hanspub.36492-ref5">5</xref>]。有学者进一步研究表明，错误的损伤修复机制所致的基因突变，可能是结核分枝杆菌药物耐受性产生的主要原因 [<xref ref-type="bibr" rid="hanspub.36492-ref6">6</xref>]。但结核分枝杆菌耐药机制的传统理论认为：结核分枝杆菌药物靶基因突变概率非常低，并且不会发生平行转移。结核分枝杆菌产生耐药是与结核分枝杆菌有很多亚群有关。在单一药物进行治疗，耐药结核分枝杆菌亚群得以不断复制，最终成为结核分枝杆菌耐药菌株，因此结核分枝杆菌应综合治疗 [<xref ref-type="bibr" rid="hanspub.36492-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.36492-ref8">8</xref>]。传统理论还表明不同半衰期的药物组成联合治疗方案，半衰期短的药物有效浓度不足便会促使结核分枝杆菌选择性耐受，并且发生基因突变 [<xref ref-type="bibr" rid="hanspub.36492-ref9">9</xref>]。但随着不断深入的研究，逐渐发现即便采用严格的正规治疗，仍然会产生耐药性细菌 [<xref ref-type="bibr" rid="hanspub.36492-ref10">10</xref>]。有学者提出“中空纤维系统模型”，该模型发现采用氟喹诺酮与低效价的二线药物联合应用，会导致结核分枝杆菌短时间内快速获得耐药性 [<xref ref-type="bibr" rid="hanspub.36492-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.36492-ref11">11</xref>]。分析耐药的原因是：1. 药物的杀菌能力、结核杆菌的耐药性与药物峰值浓度以及曲线下面积具有密切的相关性，药物峰浓度达不到最低抑菌浓度会快速放大细菌的耐药性，从而降低药物的杀菌作用；2. 在低度耐药前，或在感染初期，结核分枝杆菌携带大量的外排泵，外排泵可以保护结核分枝杆菌在药物作用下复制不遭受破坏，直到细菌发生染色体突变后具有高度耐药性 [<xref ref-type="bibr" rid="hanspub.36492-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.36492-ref12">12</xref>]。除此之外，中空纤维系统模型结果还表明，在治疗过程中药物浓度始终维持在较低的状态，会诱导结核分枝杆菌外排泵工作，最终促使基因突变，获得多耐药性 [<xref ref-type="bibr" rid="hanspub.36492-ref13">13</xref>]。</p></sec><sec id="s5"><title>3. 抗结核药物的耐药机制</title><p>治疗结核病的药物主要有四类：一线抗结核药物、二线抗结核药物、新型抗结核药物以及固定剂量的复方制剂。目前临床主要发现结核分枝杆菌对一、二线抗结核药物的耐受性。</p><sec id="s5_1"><title>3.1. 抗结核分枝杆菌一线药物</title><p>抗结核分枝杆菌的一线药物是目前治疗结核病的首选药物，主要有利福平(RFP)、异烟肼(INH)、吡嗪酰胺(PZA)、链霉素(SM)和乙胺丁醇(EMB)。抗结核一线药物主要通过干扰、抑制细菌转录过程中蛋白质合成及菌壁分枝菌酸合成，消除结核分枝杆菌。一线抗结核药物均具有半衰期相对较长，能杀灭快速增殖期及慢速繁殖期结核分枝杆菌，治疗效果好，副作用相对较少，抗菌活性较强等特点 [<xref ref-type="bibr" rid="hanspub.36492-ref14">14</xref>]。研究表明katG、inhA、pncＡ、rpsＬ、embＢ基因突变是导致结核分枝杆菌对RFP、INH、PZA、SM和EMB产生耐药的主要原因 [<xref ref-type="bibr" rid="hanspub.36492-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.36492-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.36492-ref17">17</xref>]。</p><p>katG、inhA基因是RFP主要耐药基因，二者基因突变发生率在总耐药基因中占有比在90%以上 [<xref ref-type="bibr" rid="hanspub.36492-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.36492-ref18">18</xref>]。异烟肼进入菌体后，在过氧化氢酶⁃过氧化物酶作用下，异烟肼氧化脱氢生成亲电子形式的还原型烟酰胺腺嘌呤二核苷酸(NADH)，与分枝菌酸生物合成过程中的烯酰基还原酶⁃NADH复合体相结合，进而干扰分枝菌酸的合成 [<xref ref-type="bibr" rid="hanspub.36492-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.36492-ref20">20</xref>]。katG是过氧化氢酶-过氧化物酶编码基因，所编码的过氧化氢酶-过氧化物酶可介导异烟肼药物前体活化。katG 基因点突变、部分缺失、碱基对插入均导致过氧化氢酶-过氧化物酶活性降低或缺失，抑制或阻断异烟肼转换为活性形式，引起耐药 [<xref ref-type="bibr" rid="hanspub.36492-ref21">21</xref>]。inhA基因是编码烯酰基还原酶的基因，通过干扰分枝菌酸生物合成而发挥抗结核杆菌作用，该基因突变可使异烟肼与NADH的亲和力下降而致耐药。与katG基因不同，inhA基因突变可产生低水平的异烟肼耐药，且突变频率低于katG基因 [<xref ref-type="bibr" rid="hanspub.36492-ref22">22</xref>]。</p><p>研究表明，结核分枝杆菌耐EMB与emb基因操纵子突变及其过量表达有关 [<xref ref-type="bibr" rid="hanspub.36492-ref23">23</xref>]。emb基因操纵子由embＡ、embＢ和embＣ组成，而结核分枝杆菌耐EMB分离株中embＢ突变具有相当普遍性 [<xref ref-type="bibr" rid="hanspub.36492-ref23">23</xref>]，特别是embＢ基因第306位甲硫氨酸突变为缬氨酸、异亮氨酸、亮氨酸尤为多见。因此有学者建议将embＢ基因作为快速测定耐EMB菌株标准 [<xref ref-type="bibr" rid="hanspub.36492-ref24">24</xref>]。结核杆菌对SM耐药性与编码核糖体30S亚基Ｓ12蛋白的rpsＬ基因和编码16SｒRNA的rrs基因突变有关 [<xref ref-type="bibr" rid="hanspub.36492-ref25">25</xref>]，耐SM分离株中约80%可检测出rpsＬ和rrs基因突变，而rpsＬ突变位点主要位于88和43位密码子，且基因突变率明显高于rrs基因 [<xref ref-type="bibr" rid="hanspub.36492-ref26">26</xref>]。有研究显示，PAZ 耐药分离株普遍存在由pncＡ基因突变所造成的ＰZase蛋白结构改变，而导致耐药 [<xref ref-type="bibr" rid="hanspub.36492-ref27">27</xref>]。pncＡ突变广泛分布在启动子区域和结构基因的各位点，目前发现20多个突变位点，其中发生率较高的是47位的苏氨酸置换为丙氨酸，85位亮氨酸置换为脯氨酸。</p></sec><sec id="s5_2"><title>3.2. 抗结核分枝杆菌二线药物</title><p>氟喹诺酮药物和注射类氨基糖苷类药物是治疗结核分枝杆菌的二线药物，是组成MDR-TB治疗方案的核心。但随着这两类药物在抗感染及结核病治疗中的广泛使用，耐药率也逐年增加。这两类药物的耐药不仅意味着抗结核治疗效果不佳，也意味着发展为预后更差的XDR-TB。XDR-TB 患者将面临或已处于无药可治的窘境。</p><p>氟喹诺酮类药物包括氧氟沙星、环丙沙星、莫西沙星和加替沙星等抗生素，这类药物通过抑制细菌DNA 旋转酶活性，干扰细菌DNA的复制及合成，进而杀灭细菌。氟喹诺酮类药物进入菌体，氟喹诺酮类药物可与DNA旋转酶的Gyr A和Gyr B亚单元结合，并嵌入到复制状况下的DNA链中，形成一个无DNA 旋转酶活性的三聚体复合物(DNA旋转酶-DNA-氟喹诺酮)，使细菌DNA复制受阻，从而起到杀灭细菌的作用 [<xref ref-type="bibr" rid="hanspub.36492-ref28">28</xref>]。有研究结果提示gyr A基因、gyr B基因中喹诺酮耐药决定区(quinolone resistance-determining region, QRDR)发生突变，导致氟喹诺酮类药物与DNA旋转酶Gyr A和Gyr B亚单元结合力下降，不能有效抑制DNA旋转酶活性，导致细菌对氟喹诺酮类药物耐受 [<xref ref-type="bibr" rid="hanspub.36492-ref29">29</xref>]。有学者表明结核分枝杆菌DNA旋转酶的gyr A亚单元编码基因第94及90位密码子的突变，严重干扰与氟喹诺酮类药物结合，进而导致结核分枝杆菌耐药 [<xref ref-type="bibr" rid="hanspub.36492-ref30">30</xref>]。Kandler等的研究认为gyrA基因突变与抗结核药物浓度和结构相关，导致氟喹诺酮类药物中至高度耐药；而gyrB基因突变则改变细胞内药物蓄积， 表现为低水平耐药 [<xref ref-type="bibr" rid="hanspub.36492-ref31">31</xref>]。</p><p>氨基糖苷类抗生素是治疗MDR-TB的核心二线药物，主要包括阿米卡星、卡那霉素以及它的衍生物丁胺卡那霉素。氨基糖苷类抗生素通过干扰蛋白质的翻译而导致细菌死亡。在蛋白质翻译过程中，多肽链每增加一个氨基酸均需要进位、转肽和移位。氨基糖苷类抗生素通过与核糖体的16SrRNA的核糖小体结合，能有效阻碍氨基酸的进位，从而抑制蛋白质的生物合成 [<xref ref-type="bibr" rid="hanspub.36492-ref25">25</xref>]。已有研究证明，氨基糖苷类药物耐药与核糖体的16SrRNA编码基因rrs突变显著相关，且多导致高水平耐药 [<xref ref-type="bibr" rid="hanspub.36492-ref26">26</xref>]。氨基糖苷类药物耐药与eis基因启动子点突变也明显相关 [<xref ref-type="bibr" rid="hanspub.36492-ref32">32</xref>]，eis 基因启动子突变显著提高了eis基因的转录及相应的Eis蛋白表达水平。而eis 蛋白可以使氨基糖苷类药物乙酰化，药物分子结构发生改变,从而失去抗菌活性 [<xref ref-type="bibr" rid="hanspub.36492-ref33">33</xref>]。</p></sec><sec id="s5_3"><title>3.3. 新型抗结核药物</title><p>贝达喹啉是美国FDA批准上市的首个治疗耐多药结核的新型抗结核药物，也是近50年第一个以新作用机制上市的抗结核药物 [<xref ref-type="bibr" rid="hanspub.36492-ref34">34</xref>]。贝达喹啉主要通过与结核分枝杆菌ATP合酶的低聚物和脂蛋白亚基c结合，抑制结核分枝杆菌ATP的合成，导致细菌的死亡，达到抗结核的作用 [<xref ref-type="bibr" rid="hanspub.36492-ref35">35</xref>]。与现有的抗结核药物比较，贝达喹啉具有全新的抗结核机制，与现有抗结核药物无交叉耐药。对耐药和未耐药的结核分枝杆菌均有较好的治疗效果 [<xref ref-type="bibr" rid="hanspub.36492-ref36">36</xref>]。此外还有一些新型抗结核药物处于临床试验阶段。这类药物的耐药情况报道较少。</p></sec><sec id="s5_4"><title>3.4. 复方抗结核制剂</title><p>复方抗结核制剂是将几种一线抗结核药物按照一定的剂量制成的一种复合制剂。目前世界卫生组织(WHO)和世界抗结核病及肺病联合会(IUATLD)均提倡使用复方抗结核制剂作为结核病治疗的基本方法 [<xref ref-type="bibr" rid="hanspub.36492-ref37">37</xref>]。当前复方抗结核制剂主要有二联制剂(利福平–异烟肼)、三联制剂(利福平–异烟肼–吡嗪酰胺)以及四联制剂(利福平–异烟肼–吡嗪酰胺–乙胺丁醇) [<xref ref-type="bibr" rid="hanspub.36492-ref38">38</xref>]。</p><p>总而言之，抗结核药物作用的靶点及相关代谢酶基因突变是导致结核分枝杆菌耐药的根本原因，进而引起抗结核药物无法有效杀灭结核分枝杆菌。随着临床新型抗结核分枝杆菌药物的研发及使用，将发现新的结核分枝杆菌耐药机制。及时了解和监控结核分枝杆菌的耐药情况变化，可以有效指导临床合理使用抗菌药物，更好地控制结核分枝杆菌耐药性的发生和扩散。</p></sec></sec><sec id="s6"><title>文章引用</title><p>杨 兰,吴秋莲. 结核分枝杆菌耐药分子机制的研究进展Research Progress on Molecular Mechanism of Drug Resistance of Mycobacterium tuberculosis[J]. 临床医学进展, 2020, 10(07): 1292-1297. https://doi.org/10.12677/ACM.2020.107196</p></sec><sec id="s7"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.36492-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">尤媛媛, 任鹏飞, 陈裕. 河南省传染病医院耐多药结核病患者危险因素分析[J]. 河南医学研究, 2020, 29(12): 2122-2124.</mixed-citation></ref><ref id="hanspub.36492-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">张懿行, 王伟炳, 李小攀, 等. 454例不规则治疗肺结核患者复发的相关因素分析[J]. 上海预防医学, 2019, 31(12): 1015-1019.</mixed-citation></ref><ref id="hanspub.36492-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Hawn, T.R., Day, T.A., Scriba, T.J., et al. (2014) Tuberculosis Vaccines and Prevention of Infection. Microbiology and Molecular Biology Reviews, 78, 650-671. &lt;br&gt;https://doi.org/10.1128/MMBR.00021-14</mixed-citation></ref><ref id="hanspub.36492-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">韦媛媛, 杨帆, 汤杰, 等. 抗结核药物的研究进展[J]. 中国药科大学学报, 2020, 51(2): 231-239.</mixed-citation></ref><ref id="hanspub.36492-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Schito, M., Migliori, G.B., Fletcher, H.A., et al. (2015) Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines. Clinical Infectious Diseases, 61, S102-S118. &lt;br&gt;https://doi.org/10.1093/cid/civ609</mixed-citation></ref><ref id="hanspub.36492-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Dheda, K., Gumbo, T., Gandhi, N.R., et al. (2014) Global Control of Tuberculosis: From Extensively Drug-Resistant to Untreatable Tuberculosis. The Lancet Respiratory Medicine, 2, 321-338.  
&lt;br&gt;https://doi.org/10.1016/S2213-2600(14)70031-1</mixed-citation></ref><ref id="hanspub.36492-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">闫莉, 关福源, 钟明浩, 等. 2018年结核病耐药情况及影响因素分析[J]. 中国实验诊断学, 2020, 24(4): 539-542.</mixed-citation></ref><ref id="hanspub.36492-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">邢小微. 宏基因组高通量测序对中枢神经系统感染性疾病的诊断价值研究[D]: [博士学位论文]. 北京: 中国人民解放军医学院, 2019.</mixed-citation></ref><ref id="hanspub.36492-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">李勇. 耐药结核病的研究进展[J]. 中国处方药, 2019, 17(4): 21-22.</mixed-citation></ref><ref id="hanspub.36492-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Churchyard, G., Kim, P., Shah, N.S., et al. (2017) What We Know about Tuberculosis Transmission: An Overview. The Journal of Infectious Diseases, 216, S629-S635. &lt;br&gt;https://doi.org/10.1093/infdis/jix362</mixed-citation></ref><ref id="hanspub.36492-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">王仲元. 耐药结核病的研究进展[J]. 传染病信息, 2018, 31(1): 19-23.</mixed-citation></ref><ref id="hanspub.36492-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">亢鸿飞. 结核融合蛋白疫苗FdxA-Hrp1的构建及对家兔肺部卡介苗潜伏感染模型的治疗作用研究[D]: [硕士学位论文]. 兰州: 兰州大学, 2014.</mixed-citation></ref><ref id="hanspub.36492-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Mathema, B., Andrews, J.R., Cohen, T., et al. (2017) Drivers of Tuberculosis Transmission. The Journal of Infectious Diseases, 216, S644-S653. &lt;br&gt;https://doi.org/10.1093/infdis/jix354</mixed-citation></ref><ref id="hanspub.36492-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">闫莉, 钟明浩, 关福源, 等. 结核分枝杆菌对一线抗结核药物的耐药情况分析[J]. 中国实验诊断学, 2020, 24(3): 381-384.</mixed-citation></ref><ref id="hanspub.36492-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Nahid, P., Dorman, S.E., Alipanah, N., et al. (2016) Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clinical Infectious Diseases, 63, e147-e195. &lt;br&gt;https://doi.org/10.1093/cid/ciw376</mixed-citation></ref><ref id="hanspub.36492-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, C., Liu, Y., Hu, L., et al. (2018) Molecular Mechanism of the Synergistic Activity of Ethambutol and Isoniazid against Mycobacterium tuberculosis. The Journal of Biological Chemistry, 293, 16741-16750.  
&lt;br&gt;https://doi.org/10.1074/jbc.RA118.002693</mixed-citation></ref><ref id="hanspub.36492-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">刘海涛, 姜小红. 一线抗结核药物治疗初治耐多药肺结核的效果及转归[J]. 临床医药文献电子杂志, 2020, 7(13): 174.</mixed-citation></ref><ref id="hanspub.36492-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Isakova, J., Sovkhozova, N., Vinnikov, D., et al. (2018) Mutations of rpoB, katG, inhA and ahp Genes in Rifampicin and Isoniazid-Resistant Mycobacterium tuberculosis in Kyrgyz Republic. BMC Microbiology, 18, Article No. 22.  
&lt;br&gt;https://doi.org/10.1186/s12866-018-1168-x</mixed-citation></ref><ref id="hanspub.36492-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Torres, J.N., Paul, L.V., Rodwell, T.C., et al. (2015) Novel katG Mutations Causing Isoniazid Resistance in Clinical M. tuberculosis Isolates. Emerging Microbes &amp; Infections, 4, 1-9. &lt;br&gt;https://doi.org/10.1038/emi.2015.42</mixed-citation></ref><ref id="hanspub.36492-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">王晓英, 张汇征, 罗明, 等. 结核分枝杆菌异烟肼和丙硫异烟胺耐药及其交叉耐药相关机制研究进展[J]. 中国人兽共患病学报, 2020, 36(3): 234-238+260.</mixed-citation></ref><ref id="hanspub.36492-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Siu, G.K.H., Yam, W.C., Zhang, Y., et al. (2014) An Upstream Truncation of the furA-katG Operon Confers High-Level Isoniazid Resistance in a Mycobacterium tuberculosis Clinical Isolate with No Known Resistance-Associated Mutations. Antimicrobial Agents and Chemotherapy, 58, 6093-6100. &lt;br&gt;https://doi.org/10.1128/AAC.03277-14</mixed-citation></ref><ref id="hanspub.36492-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Bollela, V.R., Namburete, E.I., Feliciano, C.S., et al. (2016) Detection of katG and inhA Mutations to Guide Isoniazid and Ethionamide Use for Drug-Resistant Tuberculosis. International Journal of Tuberculosis and Lung Disease, 20, 1099-1104. &lt;br&gt;https://doi.org/10.5588/ijtld.15.0864</mixed-citation></ref><ref id="hanspub.36492-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Richardson, M., Kirkham, J., Dwan, K., Sloan, D.J., et al. (2019) NAT2 Variants and Toxicity Related to Anti-Tuberculosis Agents: A Systematic Review and Meta-Analysis. International Journal of Tuberculosis and Lung Disease, 23, 293-316.  
&lt;br&gt;https://doi.org/10.5588/ijtld.18.0324</mixed-citation></ref><ref id="hanspub.36492-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Cao, R., Teskey, G., Islamoglu, H., et al. (2018) Characterizing the Effects of Glutathione as an Immunoadjuvant in the Treatment of Tuberculosis. Antimicrobial Agents and Chemotherapy, 62, e01132-18.  
&lt;br&gt;https://doi.org/10.1128/AAC.01132-18</mixed-citation></ref><ref id="hanspub.36492-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y., Li, Q., Gao, H., et al. (2019) The Roles of rpsL, rrs, and gidB Mutations in Predicting Streptomycin-Resistant Drugs Used on Clinical Mycobacterium tuberculosis Isolates from Hebei Province, China. International Journal of Clinical and Experimental Pathology, 12, 2713-2721.</mixed-citation></ref><ref id="hanspub.36492-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Hlaing, Y.M., Tongtawe, P., Tapchaisri, P., et al. (2017) Mutations in Streptomycin Resistance Genes and Their Relationship to Streptomycin Resistance and Lineage of Mycobacterium tuberculosis Thai Isolates. Tuberculosis and Respiratory Diseases (Seoul), 80, 159-168. &lt;br&gt;https://doi.org/10.4046/trd.2017.80.2.159</mixed-citation></ref><ref id="hanspub.36492-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Zheng, R., Zhu, C., Guo, Q., et al. (2014) Pyrosequencing for Rapid Detection of Tuberculosis Resistance in Clinical Isolates and Sputum Samples from Re-Treatment Pulmonary Tuberculosis Patients. BMC Infectious Diseases, 14, Article No. 200. &lt;br&gt;https://doi.org/10.1186/1471-2334-14-200</mixed-citation></ref><ref id="hanspub.36492-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">梁晨, 张旭霞, 邢青, 等. 北京基因型结核分枝杆菌的流行及与二线抗结核药物耐药性的相关性[J]. 中华结核和呼吸杂志, 2020, 43(4): 356-361.</mixed-citation></ref><ref id="hanspub.36492-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">苏日娜. 氟喹诺酮类药物治疗耐多药结核病临床疗效研究[J]. 中国实用医药, 2020, 15(11): 125-126.</mixed-citation></ref><ref id="hanspub.36492-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">彭芝. 喹诺酮类药物用于结核病治疗的疗效观察[J]. 中国社区医师, 2019, 35(35): 58+60.</mixed-citation></ref><ref id="hanspub.36492-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Kandler, J.L., Mercante, A.D., Dalton, T.L., et al. (2018) Validation of Novel Mycobacterium tuberculosis Isoniazid Resistance Mutations Not Detectable by Common Molecular Tests. Antimicrobial Agents and Chemotherapy, 62, e00974-18. &lt;br&gt;https://doi.org/10.1101/322750</mixed-citation></ref><ref id="hanspub.36492-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Vilchèze, C. and Jacobs Jr., W.R. (2014) Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities. In: Hatfull, G.F. and Jacobs Jr., W.R., Eds., Molecular Genetics of Mycobacteria, 2nd Edition, John Wiley &amp; Sons, Inc., Hoboken, 431-453. &lt;br&gt;https://doi.org/10.1128/9781555818845.ch22</mixed-citation></ref><ref id="hanspub.36492-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Cliff, J.M., Kaufmann, S.H.E., McShane, H., et al. (2015) The Human Immune Response to Tuberculosis and Its Treatment: A View from the Blood. Immunological Reviews, 264, 88-102. &lt;br&gt;https://doi.org/10.1111/imr.12269</mixed-citation></ref><ref id="hanspub.36492-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">毛丹, 张磊. 贝达喹啉专利申请状况分析[J]. 中国新药杂志, 2020, 29(4): 367-371.</mixed-citation></ref><ref id="hanspub.36492-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Calvert, M.B., Furkert, D.P., Cooper, C.B., et al. (2020) Synthetic Approaches towards Bedaquiline and Its Derivatives. Bioorganic &amp; Medicinal Chemistry Letters, 30, Article ID: 127172. &lt;br&gt;https://doi.org/10.1016/j.bmcl.2020.127172</mixed-citation></ref><ref id="hanspub.36492-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Turner, J. and Torrelles, J.B. (2018) Mannose-Capped Lipoarabinomannan in Mycobacterium tuberculosis Pathogenesis. Pathogens and Disease, 76, fty026. &lt;br&gt;https://doi.org/10.1093/femspd/fty026</mixed-citation></ref><ref id="hanspub.36492-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Amicosante, M., D’Ambrosio, L., Munoz, M., et al. (2017) Current Use and Acceptability of Novel Diagnostic Tests for Active Tuberculosis: A Worldwide Survey. Jornal Brasileiro de Pneumologia, 43, 380-392.  
&lt;br&gt;https://doi.org/10.1590/s1806-37562017000000219</mixed-citation></ref><ref id="hanspub.36492-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Gong, W., Liang, Y. and Wu, X. (2018) The Current Status, Challenges, and Future Developments of New Tuberculosis Vaccines. Human Vaccines &amp; Immunotherapeutics, 14, 1697-1716.  
&lt;br&gt;https://doi.org/10.1080/21645515.2018.1458806</mixed-citation></ref></ref-list></back></article>